受体酪氨酸激酶

详细介绍了VEGF受体酪氨酸激酶抑制剂的研究进展。

The inhibitor of VEGF receptor tyrosine kinase was introduced in detail .

目的探讨胰岛素受体酪氨酸激酶（TK）活性变化在胰岛素抵抗（IR）发生中的作用。

Objective To investigate the change of insulin receptor tyrosine kinase ( TK ) activity in the pathogenesis of insulin resistance ( IR ) .

以EGFR家族受体酪氨酸激酶为靶点的抗肿瘤治疗研究进展

Advances in anti-tumor therapy targeting the EGFR family of receptor tyrosine kinases

螺旋藻提取物对表皮生长因子受体酪氨酸激酶的抑制作用及诱导HL-60细胞凋亡

Inhibitory effect of spirulina extract on EGFR tyrosine kinase and its ability to induce apoptosis in HL-60 cells

非受体酪氨酸激酶ARG与过氧化氢酶相互作用机制的初步研究

Interaction of non-receptor tyrosine kinase Arg and catalase

cCbl可以介导受体酪氨酸激酶和非受体酪氨酸受体激酶的降解。

Some studies reported that c Cbl exerted the negative regulation to receptor tyrosine kinases and non receptor tyrosine kinases by promoting their degradation .

受体酪氨酸激酶c-kit及其配体SCF在正常肝及肝癌组织中的共表达

Co-expression of receptor tyrosine kinase c-kit and its ligand SCF in normal liver and hepatocellular carcinoma tissues

血小板源性生长因子α和β受体酪氨酸激酶抑制剂对兔PVR的治疗作用

Therapeutic effect of platelet-derived growth factor α and β receptor tyrosine kinase inhibitor on rabbit proliferative vitreoretinopathy

Ras是一个原癌基因，具有GTPase活性，通过受体酪氨酸激酶激活信号传导级联反应。

The Ras is a proto-oncogene , have GTPase activity , through receptor tyrosine kinases activate signaling cascade .

凋亡诱导因子与非受体酪氨酸激酶c-Abl的相互作用

Study on Interaction Between Apoptosis-Inducing Factor and Non-Receptor Tyrosine Kinase C-Abl

目前有单克隆抗体与小分子受体酪氨酸激酶抑制剂两类EGFR抑制剂在临床治疗中取得成功。

Two classes of anti-EGFR agents , monoclonal antibodies and small molecules targeting the receptor tyrosine kinase , have shown antitumor activity in clinical application .

目的研究人胚胎发育不同时期卵黄囊和胎肝内受体酪氨酸激酶（KDR）、血管内皮生长因子（VEGF）和CD34的分布及表达，为胚胎造血分化提供理论依据。

Objective To study the expression and distribution of KDR , VEGF and CD34 in yolk sac and liver of human embryo at different development stage .

其作用于内皮细胞特异性受体酪氨酸激酶（Tie-2）发挥作用。

They function as ligands for the endothelial-specific receptor tyrosine kinase ( Tie-2 ) .

方法建立体外培养小鼠耳蜗螺旋神经节细胞的方法，并进行神经丝蛋白（NF）免疫组化染色鉴定及受体酪氨酸激酶C（TrKC）免疫组化染色。

Methods The SGCs were cultured and purged in vitro . SGCs were identified by neurofilament ( NF ) and receptor tyrosine kinase C ( TrKC ) immunocytochemical staining .

EGFR与配体结合后，受体酪氨酸激酶自磷酸化，激活包括RAS通路在内的下游信号通路，调控细胞增殖、分化。

Connection of EGFR and its ligand will result in autophosphorylation of receptor tyrosine kinase following by downstream pathways activation included RAS pathway to regulate proliferation and differentiation .

VEGF对IK的抑制作用可以被受体酪氨酸激酶的抑制剂所取消，提示VEGF抑制IK的作用可能与激活该酶活性有关。

The inhibitory effect of VEGF on IK was abolished by genistein , a specific tyrosine kinase inhibitor , which suggested that this effect might be related to the stimulation of the activity of this kinase .

FLT-3受体酪氨酸激酶抑制剂的研究进展

Advances in the inhibitors of FLT-3 receptor tyrosine kinase

胰岛素受体酪氨酸激酶活性改变可能是MODS患者胰岛素抵抗发生的分子基础。

Down regulation of insulin receptors and the change of TPK activity might be a key factor in the mechanism by which the MODS patients developed insulin resistance .

人体子宫肌层和平滑肌瘤组织中胰岛素受体酪氨酸激酶活性与底物1（IRS-1）的表达

Insulin receptor tyrosine kinase activity and substrate 1 ( IRS-1 ) expression in human myometrium and leiomyoma

非受体酪氨酸激酶c-Abl与Siva-1相互作用及在细胞凋亡中的功能研究

Interaction between non-receptor tyrosine kinase c-Abl and Siva-1 in cell apoptosis

PTK787因其对肿瘤抑制的出色疗效、口服生物利用度高等特点而成为VEGF受体酪氨酸激酶抑制剂中的佼佼者。

PTK787 is the most promising VEGF receptor-tyrosine kinase inhibitor in pipeline because of its potency in tumor inhibition and oral bioavailability .

目的探讨Ⅲ型受体酪氨酸激酶信号通路中PDGFRβ以及SHIP等基因突变和单核苷酸多态性（SNP）在急性髓系白血病（AML）发病中的意义。

Objective To investigate the significance nf mutation and single nucleotide polymorphism ( SNP ) of class ⅲ receptor tyrosine kinases such as PDGFR β and SHIP in acute myeloid leukemia ( AML ) patients .

分化后的细胞中受体酪氨酸激酶c-Ret表达量明显增加。

After differentiation the expression of c-Ret , a receptor tyrosine kinase was up-regulated .

c-Abl激酶是一种非受体酪氨酸激酶，它参与多种受体引起的信号转导，并且参与了F-肌动蛋白依赖的细胞骨架变化。

C-Abl kinase as a non-receptor protein tyrosine kinase plays an essential role in signaling transduction from various receptors and in F-actin reassembly .

非受体酪氨酸激酶c-Abl广泛表达于人和哺乳动物等的细胞中并受到严格调控，通过蛋白之间相互作用、与DNA相互作用及其酪氨酸激酶活性在一系列的重要生命活动中发挥调节作用。

The c-abl gene is expressed ubiquitously as a non-receptor tyrosine kinase in mammalian and human cells . c-Abl is implicated in many important cellular process by multiple protein-protein , protein-DNA interaction and its tyrosine kinase activity .

接头蛋白c-Crk参与受体酪氨酸激酶的信号转导；

Adaptor protein ( c-Crk ) participates in receptor tyrosine kinase-singnal transduction .

吉非替尼（gefitinib，Iressa，zD1839）是一种口服选择陛表皮生长因子受体酪氨酸激酶抑制剂。

Gefitinib ( Iressa , ZD1839 ) is a selective EGFR-TK ( epidermal growth factor recep-tor tyrosine kinase ) inhibitor .

综述了表皮生长因子受体酪氨酸激酶的ATP竞争性抑制剂的研究进展，介绍了抑制剂结合受体蛋白的方式及其作用机理，重点介绍了可逆抑制剂和不可逆抑制剂的作用机理及其构效关系。

This article reviews the recent research progress in ATP competitive inhibitors of epidermal growth factor receptor . The binding manner and inhibiting mechanism are introduced , with an emphasis on the mechanism and structure-activity relationship of both reversible and irreversible inhibitors .

了解dok蛋白是如何特异地与受体酪氨酸激酶作用的对理解其功能有重要意义。

How doks specifically recognize the receptor tyrosine kinases is the key for understanding their functions .

以表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）为基础的分子靶向药物治疗在肺癌的治疗中发挥着重要作用，成为国内外研究的热点。

The epidermal growth factor receptor kinase inhibitors ( EGFR-TKI ) play an important role in molecular target therapy of lung cancer .